The U.S. Food and Drug Administration will establish a Risk Communication Advisory Committee to counsel the agency on how to better communicate drug and medical-device risk, benefit and safety issues to consumers and medical professionals, according to an FDA release issued today.
The move is a direct result of recommendations made last year in the Institute of Medicines The Future of Drug Safety report, which detailed the lack of adequate and consistent monitoring of safety issues once medical products receive FDA approval. In the report, the IOM called on Congress to establish a committee that would improve the FDAs communication of such concerns to the public.
Under the FDAs plan, the Risk Communication Advisory Committee will be made up of 15 non-FDA employees who are experts in a variety of pertinent fields, including risk communications, social marketing, health literacy, cultural competency, journalism, bioethics, and behavioral and social sciences. It will also include citizen members who can provide real-life perspective on how consumers use medical products and respond to warnings. Committee-member nomination information can be viewed here. -- by Shawn Rhea